Loading...
Market
How many new users will adopt Insulet's Omnipod 5 by end of 2024?
2
Resolution / Starting Odds
Less than 50,000 • 25%
50,000 to 100,000 • 25%
100,000 to 150,000 • 25%
More than 150,000 • 25%
Insulet Corp's official reports or press releases
Story
FDA Approves Insulet's Omnipod 5 for Type 2 Diabetes in Adults
Aug 27, 2024, 12:40 PM
The U.S. Food and Drug Administration (FDA) has granted clearance for the Omnipod® 5 Automated Insulin Delivery System, developed by Insulet Corp, to be used by individuals with Type 2 diabetes. This marks the first time an automated insulin dosing device has been approved for Type 2 diabetes patients, specifically those aged 18 and older. The device, which incorporates Insulet's SmartAdjust technology, aims to simplify diabetes management by automating insulin delivery, potentially reducing errors and improving patient outcomes. With approximately 30 million Americans diagnosed with Type 2 diabetes, of which 6 million require insulin and 2.5 million are on multiple daily injections, this development could significantly impact diabetes care. The FDA's decision is part of a broader effort to increase access to innovative diabetes management technologies. Insulet's stock, trading under the ticker $PODD, saw a 1.5% increase in pre-market trading following the announcement.
View original story
Similar markets
Less than 100 • 25%
100 - 500 • 25%
500 - 1000 • 25%
More than 1000 • 25%
Less than 500 • 25%
500-1000 • 25%
1001-2000 • 25%
More than 2000 • 25%
0-10% • 25%
11-25% • 25%
26-50% • 25%
More than 50% • 25%
Yes • 50%
No • 50%
Less than $500 million • 25%
$500 million to $1 billion • 25%
$1 billion to $2 billion • 25%
More than $2 billion • 25%
< 1 million • 33%
1 - 2 million • 33%
> 2 million • 34%
Less than 20% • 25%
20%-40% • 25%
40%-60% • 25%
More than 60% • 25%
Less than 10% • 25%
10% to 20% • 25%
20% to 30% • 25%
More than 30% • 25%
0-1 • 25%
2-5 • 25%
6-10 • 25%
More than 10 • 25%
Less than 100 • 33%
100 to 500 • 34%
More than 500 • 33%
Less than 100 • 33%
100 to 500 • 33%
More than 500 • 33%